

# Will G Dixon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421940/publications.pdf>

Version: 2024-02-01

172  
papers

10,071  
citations

44069

48  
h-index

37204

96  
g-index

194  
all docs

194  
docs citations

194  
times ranked

11517  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using patient-generated health data in clinical practice: How timing influences its function in rheumatology outpatient consultations. Patient Education and Counseling, 2022, 105, 625-631.	2.2	6
2	Sleep Disturbance and Quality of Life in Rheumatoid Arthritis: Prospective mHealth Study. Journal of Medical Internet Research, 2022, 24, e32825.	4.3	13
3	Heterogeneity in the association between weather and pain severity among patients with chronic pain: a Bayesian multilevel regression analysis. Pain Reports, 2022, 7, e963.	2.7	9
4	Using patient-reported data from a smartphone app to capture and characterize real-time patient-reported flares in rheumatoid arthritis. Rheumatology Advances in Practice, 2022, 6, rkac021.	0.7	5
5	The Influence of Chronic Pain on Social Care Service Use in the UK. Journal of Long-Term Care, 2022, .	1.1	0
6	Findability of UK health datasets available for research: a mixed methods study. BMJ Health and Care Informatics, 2022, 29, e100325.	3.0	1
7	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. Rheumatology, 2022, 61, 4845-4854.	1.9	4
8	Better digital health data should be the foundation to transform outpatient consultations for people living with long-term conditions. Journal of the Royal Society of Medicine, 2022, , 014107682210890.	2.0	2
9	The impact of moderator by confounder interactions in the assessment of treatment effect modification: a simulation study. BMC Medical Research Methodology, 2022, 22, 88.	3.1	3
10	P066â€fCOVID Voices: co-produced research to explore the shielding experiences of people with inflammatory musculoskeletal disease. Rheumatology, 2022, 61, .	1.9	0
11	P068â€fMonitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. Rheumatology, 2022, 61, .	1.9	0
12	P078â€fInternational impact of a co-produced training video: self-examination of tender and swollen joints for people with rheumatoid arthritis. Rheumatology, 2022, 61, .	1.9	0
13	P097â€fUsing a smartphone app to better detect and characterise real-time patient-reported flares in rheumatoid arthritis. Rheumatology, 2022, 61, .	1.9	0
14	Adoption of Digital Pain Manikins for Research Data Collection: A Systematic Review. Studies in Health Technology and Informatics, 2022, , .	0.3	0
15	Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology, 2021, 60, 132-139.	1.9	22
16	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatology, The, 2021, 3, e19-e27.	3.9	49
17	Implementing disruptive technological change in UK healthcare: exploring development of a smart phone app for remote patient monitoring as a boundary object using qualitative methods. Journal of Health Organization and Management, 2021, 35, 141-159.	1.3	3
18	Digital manikins to selfâ€report pain on a smartphone: A systematic review of mobile apps. European Journal of Pain, 2021, 25, 327-338.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study. Drug Safety, 2021, 44, 553-564.	3.2	8
20	Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? â€“ Authors' reply. Lancet Rheumatology, The, 2021, 3, e172-e173.	3.9	1
21	P156â€fMyositis flares are associated with reduced work productivity and fewer hours worked: illustration of the future potential of digital healthcare solutions in rheumatic diseases. Rheumatology, 2021, 60, .	1.9	0
22	P094â€fIncidence of clinically diagnosed Pagetâ€™s disease of bone: evidence of a continuing decline. Rheumatology, 2021, 60, .	1.9	0
23	Incidence of Pagetâ€™s disease of bone in the UK: evidence of a continuing decline. Rheumatology, 2021, 60, 5668-5676.	1.9	6
24	The use of narrative electronic prescribing instructions in pharmacoepidemiology: A scoping review for the International Society for Pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2021, 30, 1281-1292.	1.9	3
25	Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study. PLoS Medicine, 2021, 18, e1003829.	8.4	13
26	Understanding the Predictors of Missing Location Data to Inform Smartphone Study Design: Observational Study. JMIR MHealth and UHealth, 2021, 9, e28857.	3.7	4
27	Co-designing new tools for collecting, analysing and presenting patient experience data in NHS services: working in partnership with patients and carers. Research Involvement and Engagement, 2021, 7, 85.	2.9	5
28	Engagement with consumer smartwatches for tracking symptoms of individuals living with multiple long-term conditions (multimorbidity): A longitudinal observational study. Journal of Multimorbidity and Comorbidity, 2021, 11, 263355652110627.	2.2	4
29	Perceptions of opioid use and impact on quality of life in patients with musculoskeletal conditions within online health community forums. Rheumatology Advances in Practice, 2021, 5, rkab078.	0.7	0
30	How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence. Arthritis Care and Research, 2020, 72, 489-497.	3.4	7
31	Providing â€“the bigger pictureâ€™: benefits and feasibility of integrating remote monitoring from smartphones into the electronic health record. Rheumatology, 2020, 59, 367-378.	1.9	75
32	O18â€fNational variation and factors associated with long-term opioid use for non-cancer pain in the first year of use. Rheumatology, 2020, 59, .	1.9	0
33	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods â€“ a qualitative study. BMC Rheumatology, 2020, 4, 47.	1.6	9
34	Remote symptom monitoring integrated into electronic health records:ÂÂ systematic review. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1752-1763.	4.4	41
35	Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. PLoS Medicine, 2020, 17, e1003270.	8.4	81
36	Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety, 2020, 29, 1540-1549.	1.9	13

#	ARTICLE	IF	CITATIONS
37	P59â€fSocial care use in people with chronic pain. Rheumatology, 2020, 59, .	1.9	0
38	Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. Journal of the American Geriatrics Society, 2020, 68, 1494-1503.	2.6	16
39	Are weather conditions associated with chronic musculoskeletal pain? Review of results and methodologies. Pain, 2020, 161, 668-683.	4.2	23
40	Patient discussions of glucocorticoid-related side effects within an online health community forum. Annals of the Rheumatic Diseases, 2020, 79, 1121-1122.	0.9	6
41	Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1665-1666.	0.9	2
42	The effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes: a retrospective cohort study. BMC Rheumatology, 2020, 4, 4.	1.6	6
43	Weather Patterns Associated with Pain in Chronic-Pain Sufferers. Bulletin of the American Meteorological Society, 2020, 101, E555-E566.	3.3	10
44	Modeling of cumulative effects of time-varying drug exposures on within-subject changes in a continuous outcome. Statistical Methods in Medical Research, 2020, 29, 2554-2568.	1.5	8
45	Progress in Characterizing the Human Exposome: a Key Step for Precision Medicine. Yearbook of Medical Informatics, 2020, 29, 115-120.	1.0	9
46	Engagement and Participant Experiences With Consumer Smartwatches for Health Research: Longitudinal, Observational Feasibility Study. JMIR MHealth and UHealth, 2020, 8, e14368.	3.7	43
47	Digital methods to enhance the usefulness of patient experience data in services for long-term conditions: the DEPEND mixed-methods study. Health Services and Delivery Research, 2020, 8, 1-128.	1.4	3
48	Development of a Mobile Digital Manikin to Measure Pain Location and Intensity. Studies in Health Technology and Informatics, 2020, 270, 946-950.	0.3	5
49	Patient discussions of glucocorticoid-related side effects within an online community health forum. Clinical Medicine, 2019, 19, 91-91.	1.9	1
50	How the weather affects the pain of citizen scientists using a smartphone app. Npj Digital Medicine, 2019, 2, 105.	10.9	49
51	A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. BMC Rheumatology, 2019, 3, 41.	1.6	18
52	O17â€fChanging trends and prescribing patterns in opioid treated primary care patients with non-cancer pain over a 10-year period. Rheumatology, 2019, 58, .	1.9	0
53	O19â€fThe association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Rheumatology, 2019, 58, .	1.9	0
54	P01â€fIncidence of juvenile idiopathic arthritis in the United Kingdom: estimates from a national primary care dataset. Rheumatology, 2019, 58, .	1.9	3

#	ARTICLE	IF	CITATIONS
55	Multinational comparison of new antidepressant use in older adults: a cohort study. <i>BMJ Open</i> , 2019, 9, e027663.	1.9	28
56	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
57	Maximizing Engagement in Mobile Health Studies. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 159-172.	1.9	108
58	Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 179-186.	1.9	13
59	Collecting Symptoms and Sensor Data With Consumer Smartwatches (the Knee OsteoArthritis, Linking) Tj ETQq1 1 0.784314 rgBT /Qv Protocols, 2019, 8, e10238.	1.0	18
60	Associations Between Engagement With an Online Health Community and Changes in Patient Activation and Health Care Utilization: Longitudinal Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2019, 21, e13477.	4.3	18
61	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2018, , 121-161.	0.1	4
62	Assumptions made when preparing drug exposure data for analysis have an impact on results: <scp>A</scp>n unreported step in pharmacoepidemiology studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 781-788.	1.9	39
63	Using technology to support clinical care and research in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 276-281.	4.3	41
64	Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis. <i>BMJ Open</i> , 2018, 8, e018752.	1.9	19
65	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47
66	Supplementing electronic health records through sample collection and patient diaries: A study set within a primary care research database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 239-242.	1.9	6
67	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	1.9	43
68	Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e5-e5.	0.9	3
69	Representativeness of a digitally engaged population and a patient organisation population with rheumatoid arthritis and their willingness to participate in research: a cross-sectional study. <i>RMD Open</i> , 2018, 4, e000664.	3.8	7
70	228â€fGlucocorticoid-associated adrenal insufficiency in patients with rheumatoid arthritis: a study combining direct data collection with electronic health records. <i>Rheumatology</i> , 2018, 57, .	1.9	0
71	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). <i>BMJ: British Medical Journal</i> , 2018, 363, k3532.	2.3	268
72	Ability to Predict New-Onset Psychological Distress Using Routinely Collected Health Data: A Population-Based Cohort Study of Women Diagnosed With Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1065-1073.	4.9	8

#	ARTICLE	IF	CITATIONS
73	Low salivary cortisol levels in patients with rheumatoid arthritis exposed to oral glucocorticoids: a cross-sectional study set within UK electronic health records. RMD Open, 2018, 4, e000700.	3.8	3
74	The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study. Bone, 2018, 117, 83-90.	2.9	15
75	Comparative risk of respiratory depression in patients treated with opioids for non-malignant pain. Rheumatology, 2018, 57, .	1.9	0
76	Frequent discussion of insomnia and weight gain with glucocorticoid therapy: an analysis of Twitter posts. Npj Digital Medicine, 2018, 1, .	10.9	23
77	Consumer Smartwatches for Collecting Self-Report and Sensor Data: App Design and Engagement. Studies in Health Technology and Informatics, 2018, 247, 291-295.	0.3	3
78	Timing of glucocorticoid administration: a cross-sectional survey of glucocorticoid users in an online social network for health: Table 1. Rheumatology, 2017, 56, kew421.	1.9	2
79	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 654-660.	0.9	122
80	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.9	150
81	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.9	88
82	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	3.8	29
83	Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. BMJ Open, 2017, 7, e014603.	1.9	45
84	Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Research and Treatment, 2017, 165, 229-245.	2.5	157
85	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases, 2017, 76, 1509-1514.	0.9	29
86	Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink. RMD Open, 2017, 3, e000506.	3.8	11
87	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.9	77
88	Sleep and cognitive performance: cross-sectional associations in the UK Biobank. Sleep Medicine, 2017, 38, 85-91.	1.6	102
89	A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes. Pharmacoepidemiology and Drug Safety, 2017, 26, 1474-1482.	1.9	5
90	Opioids are not just an American problem. BMJ: British Medical Journal, 2017, 359, j5514.	2.3	8

#	ARTICLE	IF	CITATIONS
91	Response to: “Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?” by Nocturne et al. Annals of the Rheumatic Diseases, 2017, 76, e4-e4.	0.9	2
92	121. “PATIENTS' EXPERIENCES OF USING A SMARTPHONE APP FOR REMOTE MONITORING OF RHEUMATOID ARTHRITIS INTEGRATED INTO THE ELECTRONIC MEDICAL RECORD AND ITS IMPACT ON CONSULTATIONS. Rheumatology, 2017, 56, .	1.9	1
93	PAIN299. “ENGAGEMENT IN A UNITED KINGDOM SMARTPHONE STUDY EXAMINING THE ASSOCIATION BETWEEN WEATHER AND PAIN: PRELIMINARY RESULTS FROM CLOUDY WITH A CHANCE OF PAIN. Rheumatology, 2017, 56, .	1.9	0
94	Cloudy with a Chance of Pain: Engagement and Subsequent Attrition of Daily Data Entry in a Smartphone Pilot Study Tracking Weather, Disease Severity, and Physical Activity in Patients With Rheumatoid Arthritis. JMIR MHealth and UHealth, 2017, 5, e37.	3.7	60
95	Recruitment and Ongoing Engagement in a UK Smartphone Study Examining the Association Between Weather and Pain: Cohort Study. JMIR MHealth and UHealth, 2017, 5, e168.	3.7	41
96	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1089-1098.	5.6	83
97	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0154515.	2.5	64
98	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Annals of the Rheumatic Diseases, 2016, 75, 965-973.	0.9	179
99	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Annals of the Rheumatic Diseases, 2016, 75, 952-957.	0.9	258
100	Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Seminars in Arthritis and Rheumatism, 2016, 46, 133-141.	3.4	126
101	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology, 2016, 55, 2131-2137.	1.9	14
102	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology, 2016, 55, 2033-2039.	1.9	67
103	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1337-1345.	5.6	16
104	Smoking-Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink. Arthritis Care and Research, 2016, 68, 1598-1606.	3.4	33
105	Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nature Communications, 2016, 7, 10889.	12.8	237
106	Pharmacovigilance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. Journal of Clinical Epidemiology, 2016, 77, 101-111.	5.0	6
107	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Research and Therapy, 2016, 18, 251.	3.5	177
108	Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. European Journal of Epidemiology, 2016, 31, 1045-1055.	5.7	42



#	ARTICLE	IF	CITATIONS
109	A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis population. <i>Bone</i> , 2016, 90, 107-115.	2.9	12
110	Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink. <i>PLoS ONE</i> , 2016, 11, e0153848.	2.5	46
111	The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166468.	2.5	38
112	Who Self-Weighs and What Do They Gain From It? A Retrospective Comparison Between Smart Scale Users and the General Population in England. <i>Journal of Medical Internet Research</i> , 2016, 18, e17.	4.3	16
113	Patient Perspectives on Sharing Anonymized Personal Health Data Using a Digital System for Dynamic Consent and Research Feedback: A Qualitative Study. <i>Journal of Medical Internet Research</i> , 2016, 18, e66.	4.3	139
114	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000019-e000019.	3.8	90
115	Modelling and extraction of variability in free-text medication prescriptions from an anonymised primary care electronic medical record research database. <i>BMC Medical Informatics and Decision Making</i> , 2015, 16, 18.	3.0	29
116	Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. <i>Arthritis Care and Research</i> , 2015, 67, 1219-1229.	3.4	20
117	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	1.9	22
118	Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. <i>Arthritis Research and Therapy</i> , 2015, 17, 375.	3.5	25
119	Rheumatoid arthritis: biological drugs and risk of infection. <i>Lancet</i> , The, 2015, 386, 224-225.	13.7	12
120	O10.â€fRisk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	1.9	0
121	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.9	162
122	Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 290-305.	3.3	65
123	Problem list completeness in electronic health records: A multi-site study and assessment of success factors. <i>International Journal of Medical Informatics</i> , 2015, 84, 784-790.	3.3	121
124	Dynamic Consent: A Possible Solution to Improve Patient Confidence and Trust in How Electronic Patient Records Are Used in Medical Research. <i>JMIR Medical Informatics</i> , 2015, 3, e3.	2.6	95
125	P2.â€fIncidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i34-i35.	1.9	4
126	O23.â€fThe Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , 2014, 53, i38-i38.	1.9	0



#	ARTICLE	IF	CITATIONS
127	39.â€fNon-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i70-i70.	1.9	0
128	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Diseaseâ€related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	2.0	43
129	The safety of biologic therapies in RA-associated interstitial lung disease. <i>Nature Reviews Rheumatology</i> , 2014, 10, 284-294.	8.0	74
130	Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 628-628.	0.9	18
131	A dynamic model of patient consent to sharing of medical record data. <i>BMJ, The</i> , 2014, 348, g1294-g1294.	6.0	19
132	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 461-476.	0.8	3
133	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1517-1523.	0.9	5
134	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.9	146
135	Consensus Statements for the Use of Administrative Health Data in Rheumatic Disease Research and Surveillance. <i>Journal of Rheumatology</i> , 2013, 40, 66-73.	2.0	32
136	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	1.9	116
137	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidenceâ€Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1675-1683.	6.7	22
138	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 461-462.	0.9	33
139	Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1761-1764.	0.9	26
140	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.9	107
141	Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested caseâ€control analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1128-1133.	0.9	273
142	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	1.9	564
143	Influence of biological agents on cardiovascular disease in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 561-562.	0.9	6
144	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1810-1814.	0.9	173

#	ARTICLE	IF	CITATIONS
145	The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Research and Therapy, 2011, 13, R139.	3.5	147
146	Looking beyond incidence in the relationship between anti-tumor necrosis factor therapy and malignancy. Arthritis and Rheumatism, 2011, 63, 1773-1775.	6.7	1
147	Bisphosphonates and esophageal cancer—a pathway through the confusion. Nature Reviews Rheumatology, 2011, 7, 369-372.	8.0	20
148	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2011, 50, 1341-1342.	1.9	43
149	Is Anti-TNF Therapy Safer Than Previously Thought?. JAMA - Journal of the American Medical Association, 2011, 306, 2380-1.	7.4	10
150	The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Annals of the Rheumatic Diseases, 2011, 70, 956-960.	0.9	116
151	Quantifying the longitudinal value of healthcare record collections for pharmacoepidemiology. AMIA ... Annual Symposium proceedings, 2011, 2011, 1318-25.	0.2	9
152	The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?. Seminars in Oncology, 2010, 37, 11-19.	2.2	4
153	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. Seminars in Arthritis and Rheumatism, 2010, 40, 2-14.e1.	3.4	161
154	Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. Arthritis Care and Research, 2010, 62, 755-763.	3.4	168
155	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2010, 62, 3145-3153.	6.7	72
156	Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2010, 69, 1086-1091.	0.9	185
157	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases, 2010, 69, 522-528.	0.9	606
158	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Annals of the Rheumatic Diseases, 2010, 69, 1596-1602.	0.9	87
159	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ± therapy: results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2009, 68, 209-215.	0.9	200
160	European biologicals registers: methodology, selected results and perspectives. Annals of the Rheumatic Diseases, 2009, 68, 1240-1246.	0.9	114
161	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology, 2008, 47, 1000-1005.	1.9	67
162	The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Current Opinion in Rheumatology, 2008, 20, 138-144.	4.3	105

#	ARTICLE	IF	CITATIONS
163	The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Current Opinion in Internal Medicine, 2008, 7, 301-307.	1.5	1
164	What effects might anti-TNF treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF in cardiovascular pathophysiology. Annals of the Rheumatic Diseases, 2007, 66, 1132-1136.	0.9	107
165	Serious infection following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis and Rheumatism, 2007, 56, 2896-2904.	6.7	292
166	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2007, 56, 2905-2912.	6.7	522
167	Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Research and Therapy, 2006, 8, 111.	3.5	44
168	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism, 2006, 54, 2368-2376.	6.7	694
169	Does early rheumatoid arthritis exist?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 37-53.	3.3	25
170	Low grip strength is associated with bone mineral density and vertebral fracture in women. Rheumatology, 2005, 44, 642-646.	1.9	100
171	072. The Association Between Oral Glucocorticoid Therapy and Mortality in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. Rheumatology, 0, , .	1.9	0
172	036. Prevalence of Adrenal Insufficiency Following Systemic Glucocorticoid Therapy Between 0 and 100%: A Systematic Review. Rheumatology, 0, , .	1.9	0